In recent years, the regulatory role of the intestine microbyota in the initiation and progress of colorectal cancer (CRC) has attracted increasing attention. In major microbial contributors, Dhut (FN) has been identified as an important pathological factor in CRC. As an oral anaerobic chemical, FN is rarely found in the low gastrointestinal tract of healthy individuals. However, in pathological conditions, it can educate the gastrointestinal tract educatically. Once rich in colorectal environment, increasing evidence suggests that FN CRC is included in many aspects of pathogenesis, including initiation, progress, metastasis and traditional remedies such as chemotherapy, radiotherapy and immunotherapy.

A recent review by Vai Vai and Diwai Zheng’s team in the Institute of Process Engineering systematically outlined the pathogenic system of FN in CRC and summoned both current and emerging strategies for its medical targeting. In addition, writers propose potential approaches to remove existing challenges in FN modulation, which aims to facilitate more effective therapeutic interventions and improve clinical results.

Focusing on dual themes of “pathological mechanisms and therapeutic strategies”, this review first gives details of the versatile roles of FN in CRC progress. This suggests how FN contributes to the disease through processes such as microbial colonization, activism of oncogenic signaling routes and modulation of immune micro -generation. Major virus factor – such as FADA, Fap2, and Radd -Tumor’s development and their roles in resistance to treatment are highlighted. Given its tumor promoting effects, elimination of FN is considered a promising strategy for improving CRC results. The review systematically discusses various medical approaches targeting FN, including,-molecules inhibitors (such as antibiotics and natural extracts), nanomedicine (such as inorganic nanocations and organic polymers) and bioframacutics (such as antimacrobial peptides and fishes). While these approaches have exhibited capacity in pre -priclynical studies, they still face major challenges, including limited specificity, systemic poisoning, and dissolution of microbial homeostasis.

As our understanding of the pathogenic system of FN is deeper, expected to emerge from highly specific and low toxicity intervention, CRC leads treatment to greater accuracy, efficiency and privatization. This review underlines many promising directions of the future:

Sub-species-targeted intervention: Medical targeting of FN subspecies remains unspecified. Future strategies can focus on major strains like Destroy And their specific virus factor to enable personal treatment.

Intracellular clearance: Since FN can survive and repeat within tumors and immune cells, the development of strategies capable of eliminating intracellular FN is important to control its immune theft and firmness.

Vaccine development: Vaccines represent a powerful tool for specific immune protection. The target of FN-specific virus factor or host-interaction receptors can enable accurate withdrawal. However, future work should address adaptation Antigen Selection and auxiliary combinations to increase immunogenity and Efficacy,

Collectively, these emerging strategies serve as valuable references to remove current boundaries and develop micro-organisms targeted in cancer associated with CRC and other microbyota.